Beyond antivirals: Addressing Epstein‑Barr virus, health inequities, and systemic immune dysregulation in multiple sclerosis
Original framing: “Best treatment for multiple sclerosis may be antivirals” — New Scientist
Rigorous randomized controlled trials are still needed to confirm that antiviral therapy reduces MS progression, and to delineate which patient sub‑groups benefit most. Molecular studies demonstrate that EBV latency proteins can mimic host signaling pathways, but causality remains probabilistic rather than deterministic. A scientific approach must integrate virology, immunology, and systems biology to avoid reductionist conclusions.
The antiviral promise for multiple sclerosis must be situated within a broader systemic matrix that includes viral ecology, social inequities, and cultural understandings of health.
Historical precedents show that viral triggers interact with host immunity in complex ways, and cross‑cultural evidence suggests that early EBV exposure coupled with protective lifestyle factors can modulate disease risk. By weaving scientific rigor with indigenous remedies, artistic narratives, and trickster insights, we can design integrated therapeutic and public‑health strategies that are both biologically effective and socially just. Key actors—research institutions, pharmaceutical firms, public‑health agencies, and community organizations—must coordinate to fund inclusive trials, disseminate preventive education, and ensure equitable access to emerging treatments.